Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO).

Full DD Report for AVEO

You must become a subscriber to view this report.


Recent News from (NASDAQ: AVEO)

Novavax: A Break In The Action
Buy The Decline Novavax ( NVAX ) is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company recently reported quarter 3 earnings earlier this month missing on revenue by $1.89 ...
Source: SeekingAlpha
Date: December, 03 2018 03:58
AVEO Oncology to Present at the 30th Annual Piper Jaffray Healthcare Conference
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time. The conference is being held at the Lotte New Yor...
Source: Business Wire
Date: November, 20 2018 07:00
Biotech Analysis Central Pharma News: Johnson & Johnson's Partnership, Dynavax's Advancements, Aveo's Positive Results
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Johnson & Johnson Acquires Rights To A Drug That Treats Rare Forms Of Cancer News: Recently, Johnson & Johnson ( JNJ ) announced that it had ...
Source: SeekingAlpha
Date: November, 07 2018 16:20
Cancer Research Highlight: AVEO Oncology Hatches Its Big Breakout In Kidney Cancer
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you missed it, I recently p...
Source: SeekingAlpha
Date: November, 07 2018 08:00
Big Month For AVEO Pharmaceuticals Inc.
Editor's note: Seeking Alpha is proud to welcome Joseph Heglin as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Tivozanib ...
Source: SeekingAlpha
Date: November, 06 2018 15:21
IBI Research On Exelixis: A Stellar Growth Stock With Many Developments
If you want to have a better performance than the crowd, you must do things differently from the crowd. - Value Investor (Sir John Templeton) Amid the bear market that is hitting bioscience stocks lately, we strongly believe that investors should increase their research due diligence and...
Source: SeekingAlpha
Date: November, 05 2018 23:24
AVEO Oncology up 17% on positive test results
The company's TIVO-3 trial to compare tivozanib (FOTIVDA®) to sorafenib met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival (PFS). More news on: AVEO Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...
Source: SeekingAlpha
Date: November, 05 2018 17:09
AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint
- First and Only Positive Phase 3 Study in Third- and Fourth-Line RCC - - Primary Endpoint Shows 44% Improvement in Median PFS and 26% Reduction in Risk of Progression or Death (HR=0.74, p=0.02) for Tivozanib Compared to Sorafenib - - Data for Secondary Endpoint of Overall Surviva...
Source: Business Wire
Date: November, 05 2018 16:05
AVEO Oncology to Participate in Upcoming Conferences
AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer, will participate in the following investor conferences: B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at 3:25 p.m. Eastern Time. The conference is be...
Source: Business Wire
Date: August, 28 2018 07:00
Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and AVEO Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 27, 2018 / U.S. equities closed up on Friday following Federal Reserve Chairman Jerome Powell's speech, which confirmed the Federal Reserve will gradually normalize monetary policy. According to Powell, the two risks of raising interest rates are ''moving t...
Source: ACCESSWIRE IA
Date: August, 27 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-132.081.992.101.971,114,114
2018-12-122.062.062.101.981,466,209
2018-12-112.052.032.061.96975,160
2018-12-102.012.032.041.96657,726
2018-12-072.032.022.071.951,352,553

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-13168,904320,11652.7634Short
2018-12-12188,958394,55447.8915Short
2018-12-11122,518261,08346.9268Short
2018-12-10113,893263,70643.1894Short
2018-12-07390,050561,61969.4510Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AVEO.


About AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)

Logo for AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $345,904,341 - 03/20/2018
  • Issue and Outstanding: 118,867,471 - 03/08/2018

 


Recent Filings from (NASDAQ: AVEO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 26 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 26 2018

 

 


Daily Technical Chart for (NASDAQ: AVEO)

Daily Technical Chart for (NASDAQ: AVEO)


Stay tuned for daily updates and more on (NASDAQ: AVEO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AVEO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVEO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AVEO and does not buy, sell, or trade any shares of AVEO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/